REGENXBIO (RGNX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

REGENXBIO

NasdaqGS•Healthcare•Biotechnology

$8.76-0.18(-0.02%)Pre-market

Market Cap

$424.14M

P/S

2.4x

P/B

5.9x

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

How this company scores

WeakMetricSide Score: 36/100

Strongest: Growth (14/25); weakest: Profitability (3/25).

Profitability3/25

Growth14/25

Balance Sheet & Red Flags12/25

Cash & Earnings Quality7/25

Strengths

Net cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 0.0x5y range 0.0x – 10.8x

Currently near its 4-quarter median.

P/S · 2.4x5y range 0.0x – 19.3x

Currently near its 20-quarter median.

P/B · 5.9x5y range 0.0x – 19.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $424.14M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $174.48M
Q. Revenue: $108.02M
TTM EBITDA: $-148.78M
TTM Op. Income: $-164.15M
Q. Op. Income: $29.26M
TTM Net Income: $-196.43M
Q. Net Income: $22.71M
EPS: $0.43
Shares Out.: $52.82M

$174.48M in TTM revenue grew 12.0% YoY, reaching $108.02M last quarter. TTM EBITDA of $-148.78M and TTM operating income of $-164.15M show growth is flowing through to the bottom line. However, net income is negative at $196.43M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 12% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: 30.6%
Op. Margin: 27.1%
Net Margin: 21.0%

Op. margin of 27.1% is up 323.3% YoY — cost efficiency is improving. Net margin at 21.0% Over the past year, operating margin is up 109% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 2.4x
P/B Ratio: 5.9x

P/S of 2.4x and P/B of 5.9x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $386.62M
Cash: $36.49M
Long-Term Debt: N/A
Book Value: $71.77M
D/E Ratio: N/A
Debt/EBITDA: 0.0

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-62.24M
TTM Free Cash Flow: $-249.67M
FCF Margin: -143.1%
FCF / Net Income: 1.3

TTM FCF of $-249.67M on $-62.24M in operating cash flow. The FCF / Net Income ratio of 1.3x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 5 consecutive quarters — a weakening trend.